Effects of carvedilol early after myocardial infarction: Analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN)
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
In the CAPRICORN trial, carvedilol reduced all-cause mortality by 23% over a mean
follow-up of 1.3 years in clinically stabilized post-myocardial infarction (MI) patients
with left ventricular dysfunction (LVD) with or without signs of heart failure. This
analysis sought to assess the impact of carvedilol within the first 30 days of randomization.